API | tetradecanoylphorbol acetate

tetradecanoylphorbol acetate Report issue

Small molecule Experimental

AACT PubChem

Active Ingredient History

NOW

12-O-Tetradecanoylphorbol-13-acetate (TPA), also commonly known as tetradecanoylphorbol acetate, tetradecanoyl phorbol acetate, and phorbol 12-myristate 13-acetate (PMA) is a diester of phorbol. It is a potent tumor promoter often employed in biomedical research to activate the signal transduction enzyme protein kinase C (PKC). The effects of TPA on PKC result from its similarity to one of the natural activators of classic PKC isoforms, diacylglycerol. TPA is a small molecule drug. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

12-o-tetradecanoylphorbol-13-acetate | tetradecanoylphorbol acetate

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (7)

Leukemia (Phase 2)

Lymphoma (Phase 1)

Multiple Myeloma (Phase 1)

Myelodysplastic-Myeloproliferative Diseases (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Myeloproliferative Disorders (Phase 1)

Precancerous Conditions (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue